COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

FDA Approves “Icy Fire” Drug Based on UC San Diego Researcher’s Findings

 

March 05, 2008  |  

A drug to treat a rare, inherited disease that causes rash, fever, chills and joint pain in patients when they are exposed to cold temperatures has been approved by the U.S. Food and Drug Administration (FDA).  The therapy, ARCALYST™ (rilonacept), marketed by Regeneron Pharmaceuticals, is based on a discovery by Hal Hoffman, M.D., associate professor of medicine at UC San Diego School of Medicine.

ARCALYST has received marketing approval for the treatment Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.   CAPS is a group of rare, inherited, auto-inflammatory conditions characterized by life-long, recurrent symptoms of rash, fever and chills, joint pain, eye pain and fatigue.  Symptoms can be triggered at any time by exposure to cooling temperatures, stress or exercise.

FCAS is an “orphan” hereditary disease that affects only about 300 people in the United States, 90 percent of them tracing their ancestry to a single person who came to America in the 1600s.   Hoffman’s team first identified the genetic basis of the disease: a mutation that causes alterations in the protein they named cryopyrin – which means “icy fire” – because cold triggers fever in patients. 

“This is a perfect example of  research that was bedside to bench…and back,” said Hoffman, who has studied FCAS by drawing blood samples at different family reunions held through the United States and interviewing hundreds of patients across the country about their symptoms.  “The approval of this drug represents a major advance in the treatment of CAPS patients.  I hope it will bring increased awareness of this rare disease, which is frequently misdiagnosed.”

Cryopyrin regulates the release of interleukin-1, an important mediator of fever and systemic inflammation during the body’s initial immune response.  Researchers found that alterations in cryopyrin lead to over-production of Il-1, which is inhibited by ARCALYST.

In clinical studies at 20 sites including UC San Diego, patients treated with the drug experienced greater improvement in overall symptoms than patients treated with a placebo.  Regeneron expects to launch ARCALYST, its first commercial product, by the end of March.  It is the only therapy currently approved for patients with CAPS.
                                                      # # #

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu




Media Contact

Share This Article


Related News

9/10/2021
UC San Diego School of Medicine receives $6.1M to launch a new research center studying the effects of maternal antibiotic use on breast milk and infant health. The center is funded by National Instit ...
9/9/2021
UC San Diego School of Medicine researchers will receive $6.4 million in National Institutes of Health grant funding to study how external signals and genetic variations influence the behavior of one ...
9/8/2021
Researchers found that breastfeeding mothers who received either the Pfizer-BioNTech or Moderna vaccination reported the same local or systemic symptoms as what has been previously reported in non-bre ...
9/7/2021
UC San Diego Health improved care for more than 32,000 Medicare beneficiaries in San Diego, Riverside, and Imperial Counties, and saved Medicare close to $7 million by utilizing population health tech ...



Follow Us